AdAlta CEO Sam Cobb provided an an update to the Morgans network in December 2018 on the progress of AdAlta’s lead candidate, AD-214. This included an update on the manufacturing of AD-214 being completed by Selexis and KBI Biopharma as well as AdAlta’s progress towards clinical trials slated to commence early 2020. The interview can be viewed below and AdAlta’s latest company presentation can be found here.
